What could CMS’s proposed changes to fixed-dose combination therapies mean for patients, providers, and the future of cancer care? In this National Minority Quality Forum (NMQF) webinar, “Not So Narrow”: Examining the Unintended Consequences of CMS’s Fixed Dose Combination Drug Proposal, patient advocates, clinicians, health equity leaders, and policy experts examine the potential consequences of proposed changes to the treatment of certain fixed-dose combination therapies under the Medicare Drug Price Negotiation Program. The discussion explores what is at stake for patients and providers, including potential implications for patient access, treatment experience, healthcare equity, treatment options, and future pharmaceutical innovation. The webinar also highlights the Health Affairs article, “When the Payer Defines the Product: How a Medicare Pricing Rule Would Deepen the Divide in Cancer Care,” which examines how CMS’s proposed treatment of fixed-dose combination therapies could affect access to more convenient forms of cancer treatment—particularly for patients facing transportation, time, employment, and other barriers to care. Moderator: Gretchen Wartman Vice President, Policy and Program ‪@nationalminorityqualityforum‬ Panelists: Margaret “Peg” Rosenzweig, PhD, FNP-BC, AOCNP, FAAN Distinguished Service Professor, University of Pittsburgh School of Nursing Director of Community Outreach and Engagement, UPMC Hillman Cancer Center Steve Horn Director, Governmental Relations ICAN, International Cancer Advocacy Network Shailee Gusani, PharmD, RPh Associate Director, U.S. Policy & Research Bristol Myers Squibb Michael Pratt Chief Communications Officer National Pharmaceutical Council Originally held August 7, 2026.